research use only

Lumiracoxib COX inhibitor

Cat.No.S2903

Lumiracoxib (COX-189) is a novel, selective COX-2 inhibitor with Ki of 0.06 μM. This compound also inhibits COX1 with Ki of 3 μM.
Jump to

Quality Control

Batch: Purity: 99.91%
99.91

Solubility

In vitro
Batch:

DMSO : 59 mg/mL (200.87 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 293.72 Formula

C15H13ClFNO2

Storage (From the date of receipt)
CAS No. 220991-20-8 Download SDF Storage of Stock Solutions

Synonyms COX-189 SMILES CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
COX-2
(Cell-free assay)
60 nM(Ki)
COX-1
(Cell-free assay)
3 μM(Ki)
In vitro
Lumumiracoxib has an IC50 of 0.14 μm in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 μm (HEK 293 cells transfected with human COX-1). In a human whole blood assay, IC50 values for this compound are 0.13 μM for COX-2 and 67 μM for COX-1 (COX-1/COX-2 selectivity ratio 515).
In vivo
Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety. This compound is rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h. Efficacy of this chemical in rat models of hyperalgesia, oedema, pyresis and arthritis is dose-dependent and similar to diclofenac. However, consistent with its low COX-1 inhibitory activity, it at a dose of 100 mg/kg orally causes no ulcers and is significantly less ulcerogenic than diclofenac.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2013-02-13)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01481610 TERMINATED
Kidney Failure, Chronic; Arthralgia
Hospital Central Sur de Pemex
2012-01 PHASE2
NCT00154219 COMPLETED
Osteoarthritis, Hip
Novartis
2004-11 PHASE3
NCT00267176 COMPLETED
Osteoarthritis; Controlled Hypertension
Novartis Pharmaceuticals
2005-11 PHASE4
NCT00348491 COMPLETED
Pain
Novartis Pharmaceuticals
2006-02 PHASE4
NCT00350155 Completed
Healthy Volunteers
Novartis
2006-05 Phase 4
NCT00348491 Completed
Pain
Novartis Pharmaceuticals|Novartis
2006-02 Phase 4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map